2. Search Result
Search Result
Results for "

PSMA inhibitor

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

3

Inhibitory Antibodies

1

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117410
    Vipivotide tetraxetan
    Maximum Cited Publications
    17 Publications Verification

    PSMA-617

    		 Drug-Linker Conjugates for ADC Cancer
    Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
    Vipivotide tetraxetan
  • HY-125399
    PSMA-11
    1 Publications Verification

    HBED-CC-PSMA

    		 PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
    PSMA-11
  • HY-W054292
    tert-Butyl-DCL

    (OtBu)KuE(OtBu)2

    		 PSMA Cancer
    Tert-Butyl-DCL is a PSMA inhibitor. Tert-Butyl-DCL Tert-Butyl-DCL can be used in the research of prostate cancer .
    tert-Butyl-DCL
  • HY-148761
    Zadavotide guraxetan
    2 Publications Verification

    PSMA I&T; PNT-2002

    		 PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    Zadavotide guraxetan
  • HY-139840
    GCPII-IN-1

    		PSMA Carboxypeptidase Cancer
    GCPII-IN-1 (Compound 2) is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 can be used in the research of prostate cancer .
    GCPII-IN-1
  • HY-P9992
    Pelgifatamab

    BAY-2315497; PSMA-TTC

    		 PSMA Apoptosis Cancer
    Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .
    Pelgifatamab
  • HY-139840A
    GCPII-IN-1 TFA

    		PSMA Carboxypeptidase Cancer
    GCPII-IN-1 (Compound 2) TFA is a GCPII (also known as PSMA) inhibitor with a Ki of 44.3 nM. GCPII-IN-1 TFA can be used in the research of prostate cancer .
    GCPII-IN-1 TFA
  • HY-160893
    PSMA-azide

    		PSMA Cancer
    PSMA-azide is a prostate-specific membrane antigen (PSMA) ligand. PSMA-azide inhibits PSMA-dependent NAAG (N-acetylaspartylglutamic acid) hydrolysis, with an IC50 of 9 nM and a Ki of 1 nM. PSMA-azide contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups .
    PSMA-azide
  • HY-141860
    PSMA-Val-Cit-PAB-MMAE

    		PSMA Microtubule/Tubulin Reactive Oxygen Species (ROS) Cytochrome P450 Cancer
    PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .
    PSMA-Val-Cit-PAB-MMAE
  • HY-147287
    Glu-urea-Glu-NHS ester

    		PSMA Drug Intermediate Cancer
    Glu-urea-Glu-NHS ester is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu. Glu-urea-Glu-NHS ester can be used for synthesis of small-molecule prostate-specific membrane antigen (PSMA) inhibitors, imaging agents (such as PSMAi-PEG conjugates), and targeted drug delivery vehicles .
    Glu-urea-Glu-NHS ester
  • HY-148152A
    PSMA I&S TFA

    		PSMA Cancer
    PSMA I&S TFA is a PSMA-targeted imaging agent. PSMA I&S TFA undergoes PSMA-mediated internalization into PSMA-expressing cells, with uptake into PSMA-positive tissues competitively inhibited by a potent PSMA inhibitor. PSMA I&S TFA can be used for the research of prostate cancer .
    PSMA I&S TFA
  • HY-114256
    EC1169

    		PSMA Cancer
    EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
    EC1169
  • HY-103345
    2-MPPA

    GPI-5693

    		 Carboxypeptidase Neurological Disease Cancer
    2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM .
    2-MPPA
  • HY-158119A
    PSMA-trillium

    Felivotide mopaxetan

    		 PSMA Cancer
    PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope 225Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA-trillium
  • HY-175744
    PSMA-MAL-5

    		PSMA Cancer
    PSMA-MAL-5 is a PSMA ligand. PSMA-MAL-5 covalently binds to Cys466 of PSMA. PSMA-MAL-5 labeled with 177Lu and 225Ac has high radiostability and tumor uptake. PSMA-MAL-5 also effectively inhibits tumor growth. PSMA-MAL-5 can be used for SPECT/CT imaging and radionuclide therapy of prostate cancer .
    PSMA-MAL-5
  • HY-129615
    MIP-1072

    		PSMA Cancer
    MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .
    MIP-1072
  • HY-123733
    MIP-1095

    RPS-001

    		 PSMA Others Cancer
    MIP-1095 potently inhibits the glutamate carboxypeptidase activity of PSMA (Ki =0.24 nM) .
    MIP-1095
  • HY-177808
    A9g sodium

    A9g aptamer sodium

    		 PSMA Cancer
    A9g sodium is an RNA aptamer that inhibits the enzymatic activity of prostate-specific membrane antigen (PSMA).
    A9g sodium
  • HY-123733A
    MIP-1095 TFA

    RPS-001 TFA

    		 PSMA Cancer
    MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( 131I labeled) as an imaging probe to indicate tumor progression. And 131I-MIP-1095 showed higher renal uptake in mice .
    MIP-1095 TFA
  • HY-P5292A
    HYNIC-iPSMA TFA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA TFA
  • HY-P991708
    Olsutamig

    REGN-4336

    		 PSMA CD3 Cancer
    Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
    Olsutamig
  • HY-P5292
    HYNIC-iPSMA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA
  • HY-149297
    PSMA-IN-1

    		PSMA Cancer
    PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a Ki value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λEX: 620 nm; λEM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer .
    PSMA-IN-1
  • HY-149869
    PSMA-IN-3

    		PSMA Cancer
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer .
    PSMA-IN-3
  • HY-149298
    PSMA-IN-2

    		PSMA Cancer
    PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .
    PSMA-IN-2
  • HY-163196
    PSMA-IN-4

    		PSMA Others
    PSMA-IN-4 (compound 9) is a potent inhibitor of PSMA, with the IC50 value of 1.2 μM .
    PSMA-IN-4
  • HY-158266
    DOTA-PSMA-EB-01

    LNC1003

    		 Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-PSMA-EB-01
  • HY-P10951
    (R)-Zadavotide guraxetan

    (R)-PSMA I&T; (R)-PNT-2002

    		 PSMA Cancer
    Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
    (R)-Zadavotide guraxetan
  • HY-169336
    CQ-16

    		PARP PSMA Cancer
    CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
    CQ-16
  • HY-168913
    CTT2274

    		PSMA Cancer
    CTT2274 is a prodrug of MMAE (HY-15162). CTT2274 is composed of a prostate-specific membrane antigen (PSMA)-binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and MMAE payload. CTT2274 shows selective binding to PSMA and delivers MMAE. CTT2274 inhibits prostate cancer .
    CTT2274
  • HY-174808
    SC691

    		PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    SC691 is a PSMA inhibitor. SC691 can be labeled with 68Ga(III). SC691 can be used for imaging diagnosis of prostate cancer .
    SC691
  • HY-174440
    BWD

    		PSMA Cancer
    BWD is a PSMA ligand (IC50 = 35.86). BWD exhibits excellent in vitro stability and high affinity. BWD can enhance tumor uptake and retention. BWD can inhibit tumor growth in vivo. BWD can be studied in anticancer research .
    BWD
  • HY-173476
    TcO-ABX474

    TcO-5

    		 PSMA Cancer
    TcO-ABX474 (TcO-5) is a potent prostate-specific membrane antigen (PSMA) inhibitor with a Kd value of 6.1 nM. TcO-ABX474 inhibits prostate cancer cell growth and metastasis. TcO-ABX474 is promising for research of prostate cancer .
    TcO-ABX474
  • HY-103345R
    2-MPPA (Standard)

    GPI-5693 (Standard)

    		 Reference Standards Carboxypeptidase Neurological Disease Cancer
    2-MPPA (Standard) is the analytical standard of 2-MPPA. This product is intended for research and analytical applications. 2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM .
    2-MPPA (Standard)
  • HY-168133
    SIRT2-IN-16

    		Sirtuin Cancer
    SIRT2-IN-16 (compund 17) is a prostate-specific membrane antigen (PSMA)-targeted SIRT2 inhibitor .
    SIRT2-IN-16
  • HY-121659
    DCFBC

    		PSMA Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
    DCFBC
  • HY-185167
    PSMA-1-DOTA

    		Cancer
    PSMA-1-DOTA is a prostate-specific membrane antigen (PSMA) binder with high affinity, enables targeted radionuclide delivery for imaging and therapy. PSMA-1-DOTA acts as a tumor growth inhibitor that reduces growth of PSMA-expressing prostate cancer tumors .
    PSMA-1-DOTA
  • HY-164575B
    NH2-NODAGA hydrochloride

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NH2-NODAGA hydrochloride is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA hydrochloride can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA hydrochloride
  • HY-P992366
    HFB200901

    		Galectin Tim3 Cancer
    HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 + T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .
    HFB200901

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: